NFE2L2 and breast carcinoma: In addition, one of the test chemicals, the PI3K inhibitor LY294002, acted as a NRF2 suppressor in the context of a constitutively active PIK3CA in the human breast cancer cell line MCF10A when tested at 20 μM (see above).